157 related articles for article (PubMed ID: 14701675)
1. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis.
Guo Q; Sahoo SP; Wang PR; Milot DP; Ippolito MC; Wu MS; Baffic J; Biswas C; Hernandez M; Lam MH; Sharma N; Han W; Kelly LJ; MacNaul KL; Zhou G; Desai R; Heck JV; Doebber TW; Berger JP; Moller DE; Sparrow CP; Chao YS; Wright SD
Endocrinology; 2004 Apr; 145(4):1640-8. PubMed ID: 14701675
[TBL] [Abstract][Full Text] [Related]
2. DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.
Vikramadithyan RK; Hiriyan J; Suresh J; Gershome C; Babu RK; Misra P; Rajagopalan R; Chakrabarti R
Obes Res; 2003 Feb; 11(2):292-303. PubMed ID: 12582227
[TBL] [Abstract][Full Text] [Related]
3. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
Doebber TW; Kelly LJ; Zhou G; Meurer R; Biswas C; Li Y; Wu MS; Ippolito MC; Chao YS; Wang PR; Wright SD; Moller DE; Berger JP
Biochem Biophys Res Commun; 2004 May; 318(2):323-8. PubMed ID: 15120604
[TBL] [Abstract][Full Text] [Related]
4. High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists.
Wang PR; Guo Q; Ippolito M; Wu M; Milot D; Ventre J; Doebber T; Wright SD; Chao YS
Eur J Pharmacol; 2001 Sep; 427(3):285-93. PubMed ID: 11567659
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues.
Way JM; Harrington WW; Brown KK; Gottschalk WK; Sundseth SS; Mansfield TA; Ramachandran RK; Willson TM; Kliewer SA
Endocrinology; 2001 Mar; 142(3):1269-77. PubMed ID: 11181544
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat.
Dana SL; Hoener PA; Bilakovics JM; Crombie DL; Ogilvie KM; Kauffman RF; Mukherjee R; Paterniti JR
Metabolism; 2001 Aug; 50(8):963-71. PubMed ID: 11474486
[TBL] [Abstract][Full Text] [Related]
7. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
Memon RA; Tecott LH; Nonogaki K; Beigneux A; Moser AH; Grunfeld C; Feingold KR
Endocrinology; 2000 Nov; 141(11):4021-31. PubMed ID: 11089532
[TBL] [Abstract][Full Text] [Related]
9. (2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.
Koyama H; Miller DJ; Boueres JK; Desai RC; Jones AB; Berger JP; MacNaul KL; Kelly LJ; Doebber TW; Wu MS; Zhou G; Wang PR; Ippolito MC; Chao YS; Agrawal AK; Franklin R; Heck JV; Wright SD; Moller DE; Sahoo SP
J Med Chem; 2004 Jun; 47(12):3255-63. PubMed ID: 15163205
[TBL] [Abstract][Full Text] [Related]
10. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.
Dressel U; Allen TL; Pippal JB; Rohde PR; Lau P; Muscat GE
Mol Endocrinol; 2003 Dec; 17(12):2477-93. PubMed ID: 14525954
[TBL] [Abstract][Full Text] [Related]
11. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
[TBL] [Abstract][Full Text] [Related]
14. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
Ye JM; Iglesias MA; Watson DG; Ellis B; Wood L; Jensen PB; Sørensen RV; Larsen PJ; Cooney GJ; Wassermann K; Kraegen EW
Am J Physiol Endocrinol Metab; 2003 Mar; 284(3):E531-40. PubMed ID: 12556350
[TBL] [Abstract][Full Text] [Related]
15. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells.
Mezei O; Banz WJ; Steger RW; Peluso MR; Winters TA; Shay N
J Nutr; 2003 May; 133(5):1238-43. PubMed ID: 12730403
[TBL] [Abstract][Full Text] [Related]
16. AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats.
Ljung B; Bamberg K; Dahllöf B; Kjellstedt A; Oakes ND; Ostling J; Svensson L; Camejo G
J Lipid Res; 2002 Nov; 43(11):1855-63. PubMed ID: 12401884
[TBL] [Abstract][Full Text] [Related]
17. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.
Chakrabarti R; Vikramadithyan RK; Misra P; Hiriyan J; Raichur S; Damarla RK; Gershome C; Suresh J; Rajagopalan R
Br J Pharmacol; 2003 Oct; 140(3):527-37. PubMed ID: 12970088
[TBL] [Abstract][Full Text] [Related]
18. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.
Kuwabara K; Murakami K; Todo M; Aoki T; Asaki T; Murai M; Yano J
J Pharmacol Exp Ther; 2004 Jun; 309(3):970-7. PubMed ID: 14982965
[TBL] [Abstract][Full Text] [Related]
19. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
Niho N; Takahashi M; Kitamura T; Shoji Y; Itoh M; Noda T; Sugimura T; Wakabayashi K
Cancer Res; 2003 Sep; 63(18):6090-5. PubMed ID: 14522940
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
Chaput E; Saladin R; Silvestre M; Edgar AD
Biochem Biophys Res Commun; 2000 May; 271(2):445-50. PubMed ID: 10799317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
